{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:42:05Z","timestamp":1788385325307,"version":"build-2803163510"},"reference-count":0,"publisher":"International Institute of Anticancer Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CDP"],"published-print":{"date-parts":[[2024,3,3]]},"abstract":"<jats:p>Background\/Aim: Elotuzumab, an anti-SLAMF7 monoclonal antibody, can enhance immune activity via elevated antibody-dependent cellular cytotoxicity and reduced SLAMF7+CD8+CD57+ regulatory T-cells (Tregs). This multicenter observational study investigated the kinetics of lymphocytes in myeloma patients treated with elotuzumab, lenalidomide, and dexamethasone (ERd) by two-color flow cytometry using peripheral blood samples. Patients and Methods: Twenty-one patients were included in this study. The median duration of ERd was 22.6 months, and the cutoff time for long-duration ERd was two years. Results: The CD2+CD16+ and CD16+CD57\u2013 NK cells were significantly increased over time in the long-duration ERd group compared to those in the short-duration ERd group (p=0.035 and p&lt;0.001). The CD8+ and CD16\u2013CD57+ lymphocytes, identified as low-activity NK cells or SLAMF7+ Tregs, were significantly increased in the patients whose ERd outcome was progressive disease (PD) compared to those in the non-PD group (p=0.023 and p&lt;0.001). The mean CD4\/CD8 ratio and CD19+ lymphocyte counts in the long-duration ERd group were significantly lower than those in the short-duration ERd group, although the kinetics of them did not change over time (p=0.016 and p=0.011). When the cutoff value of CD4\/CD8 ratio was 0.792 according to ROC curves, the two-year time to next treatment (TTNT) in the low CD4\/CD8 group was significantly longer than that in the high CD4\/CD8 group (80.0% vs. 15.0%, p=0.024). Conclusion: The change in NK cells and CD8+ Tregs predicted long-duration ERd and PD, and maintaining low CD4\/8 ratio predicted long TTNT, suggesting that these lymphocyte fractions might be biomarkers for a durable therapeutic effect of ERd in myeloma patients.<\/jats:p>","DOI":"10.21873\/cdp.10293","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T08:00:31Z","timestamp":1715241631000},"page":"97-104","source":"Crossref","is-referenced-by-count":3,"title":["NK and T-lymphocyte Kinetics Predict Outcome in Myeloma Patients Treated With Elotuzumab, Lenalidomide Plus Dexamethasone"],"prefix":"10.21873","volume":"4","author":[{"given":"KAZUHITO","family":"SUZUKI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MORIO","family":"MATSUMOTO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YASUSHI","family":"HIRAMATSU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NAOKI","family":"TAKEZAKO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YOTARO","family":"TAMAI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KENSHI","family":"SUZUKI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"9336","published-online":{"date-parts":[[2024,3,3]]},"container-title":["Cancer Diagnosis &amp; Prognosis"],"original-title":[],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T08:00:33Z","timestamp":1715241633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancerdiagnosisprognosis.org\/article\/308\/nk-and-t-lymphocyte-kinetics-predict-outcome-in-myeloma-patients-treated-with-elotuzumab-lenalidomide-plus-dexamethasone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,3]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,3,3]]},"published-print":{"date-parts":[[2024,3,3]]}},"URL":"https:\/\/doi.org\/10.21873\/cdp.10293","relation":{},"ISSN":["2732-7787"],"issn-type":[{"value":"2732-7787","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,3]]}}}